CancerDrs Find care

Breast Cancer clinical trials in New Hampshire

7 actively recruiting breast cancer trials at 6 sites across New Hampshire.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in New Hampshire:
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in New Hampshire:
  • Research Site — Hooksett, New Hampshire
  • Research Site — Lebanon, New Hampshire
  • Research Site — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in New Hampshire:
  • Dana-Farber/New Hampshire Oncology-Hematology — Londonderry, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

24GUT540 : Meeting of Breast Cancer Patients and Pathologists

Historically, most pathologists have had little direct contact or communication with patients. In the past two decades, however, there has been a modest movement toward patient-pathologist visits in which pathologists review with patients …

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT07040514
Sites in New Hampshire:
  • Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Testing a Mammography Decision Intervention in a Rural Setting

The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention.…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT06522568
Sites in New Hampshire:
  • Cheshire Medical Center — Keene, New Hampshire
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20